

# **COMPUMEDICS LIMITED**

(ACN 006 854 897)

## **ASX Half-year information 31 December 2014**

Lodged with the ASX under Listing Rule 4.2A.3

This information should be read in conjunction with the 30 June 2014 Annual Report.

### **Contents**

Results for Announcement to the Market <i>(Appendix 4D item 2)</i>	2
Half-year report <i>(ASX Listing rule 4.2A1)</i>	5
Supplementary Appendix 4D Information <i>(Appendix 4D items 3 to 9)</i>	25

**Compumedics Limited**  
**Half-year ended 31 December 2014**

(Previous corresponding period:  
Half-year ended 31 December 2013)

**Results for Announcement to the Market**

				<b>\$'000</b>
<b>Revenue</b> from continuing operations <i>(Appendix 4D item 2.1)</i>		Up 8% or \$1,155k	to	15,634
<b>Profit</b> before interest and tax (A\$'000)		Up 83% or \$571k	To	1,263
<b>Profit</b> after tax attributable to members <i>(Appendix 4D item 2.2)</i>		Up 125% or \$502k	to	904
<b>Net Profit</b> for the period attributable to members <i>(Appendix 4D item 2.3)</i>		Up 125% or \$502k	to	904

<b>Dividends/distributions</b> <i>(Appendix 4D item 2.4)</i>	Amount per security	Franked amount per security
Final dividend (prior year)	n/a	n/a

**Record date** for determining entitlements to the dividend  
*(Appendix 4D item 2.5)*

n/a

No interim dividend has been declared

**Explanation of Revenue** *(Appendix 4D item 2.6)*

The Company generated \$15.6m in revenues from the sale of goods and services, which was 8% higher than the prior corresponding half-year period (pcp). At 31 December 2014, the Company was holding \$3.8m in sales orders to ship, down from \$6.0m at 30 June 2014.

Revenues shipped and invoiced for the six-month period to 31 December 2014 were higher than the pcp due to the following factors:

- 1 The Company continued to clear the back-log of sales orders as a result of additional funding received earlier in calendar 2014 and the new facility executed with Export Finance and Investment Corporation (EFIC) in December 2014.
- 2 The Company achieved overall sales-order growth of 6% over the pcp. Importantly sales-order growth of 13% was achieved in Asia (including China), 10% in DWL (our Germany-based transcranial Doppler [TCD] business), 6% in

the USA and 4% in Australia. Europe was steady with sales orders over the pcg.

**Explanation of Profit after tax** *(Appendix 4D item 2.6)*

Profit after tax for the half-year to 31 December 2014 was \$0.9m compared to \$0.4m for the prior corresponding half-year.

The on-going improvement in the profitability of the Company over the pcg was a result of being able to ship more sales orders in the six-month period as a result of the additional funding obtained by the Company during calendar 2014. The profit also improved due to the favourable impact on margins from the initiatives undertaken by the Company to source more components directly from Asia and to also selectively move production activities to Asia. The full favourable impact of these initiatives and external circumstances will be more evident in the second half of the financial year, along with the movement in the Australian dollar compared to the US dollar, which has had a minor favourable impact in the six months to 31 December 2014.

The Company remains committed to its strategic growth plans, whilst at the same time improving productivity and efficiency throughout the business in order to continue to generate consistent and growing profits.

**Explanation of Dividends** *(Appendix 4D item 2.6 )*

No dividends were declared or paid in the period.

**Net Tangible Asset (NTA) Backing** *(Appendix 4D item 3)*

	2014	2013
Net tangible asset backing per ordinary share	4.6 cents	3.3 cents

Net tangible assets of \$7.7m divided by issued ordinary shares of 166.885m = 4.6 cents per share



**Compumedics Limited**  
**Half-year report – 31 December 2014**

<b>Contents</b>	<b>Page</b>
Directors' Report	5
Auditor's independence declaration	8
Interim financial report	
Consolidated statement of profit or loss and other comprehensive income	9
Consolidated statement of financial position	11
Consolidated statement of changes in equity	12
Consolidated statement of cash flows	13
Notes to the financial statements for the half-year ended 31 December 2014	14
Directors' declaration	22
Independent auditor's review report	23
Supplementary Appendix 4D information	25

This interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2014 and any public announcements made by Compumedics Limited during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001* and Australian Stock Exchange Listing Rules.

# Directors' Report

## Interim Report – 31 December 2014

Your directors present their report on the consolidated entity consisting of Compumedics Limited and the entities it controlled at the end of and during the half-year ended 31 December 2014.

### Directors

The following persons were directors of Compumedics Limited during the whole of the half-year and up to the date of this report, unless otherwise stated.

Dr. D. Burton  
Mr. A. Anderson  
Mr. D. Lawson

### Review of Operations

A summary of consolidated revenues and results for the half-year is set out below:

	<b>6 months ended Dec 2014</b>	<b>6 months ended Dec 2013</b>
Revenues from continuing operations (A\$'000)	15,634	14,479
Profit before interest, and tax (A\$'000)	1,263	691
Profit for the half-year (A\$'000)	904	402
Basic earnings per share (cents)	0.5	0.2
Diluted earnings per share (cents)	0.5	0.2

### Business / Product Group Performance

Group net profit after tax for the half-year to 31 December 2014 was \$0.9m compared to \$0.4m in the prior corresponding half-year. The result reflects greater shipments as a result of the additional funding received by the business during 2014, improved margins due to initiatives already noted and the depreciation of the Australian dollar against the US dollar and the Euro. The Group carried \$3.8m of sales orders on-hand into the second half of the year and expects to continue to reducing the sales orders on-hand in second half of the financial year.

The Group continues to focus on the identified growth opportunities for the Group and will pursue these in conjunction with productivity gains and cost reductions in order to continue to grow the earnings of the Group.

The Group continued to improve its financial metrics over the half-year to 31 December 2014 including:

- EBITDA for the half year to 31 December 2014 was \$1.9m compared to \$1.3m in the prior corresponding period.
- Operating cash flows were positive \$0.4m for the half-year to 31 December 2014, compared to \$0.6m in the half-year to 31 December 2013. Whilst operating cash was lower this reflects the increased production and purchasing in the first half to ensure the open sales order position continues to improve in the second half of the financial year.
- Borrowings, at 31 December 2014, of \$2.5 million were higher compared to the \$2.0m of borrowings at 30<sup>th</sup> June 2014, due to the new EFIC facility and the funds injected into manufacturing.
- Cash on hand at 31 December 2014 was \$1.6m, which was higher than the balance at 30<sup>th</sup> June 2014 at \$1.1m, reflecting increased sales in November and improved cash inflows as a consequence.

### **Explanation of non-IFRS measures of performance**

	<b>31 Dec 2014</b>	<b>31 Dec 2013</b>
	<b>\$'000</b>	<b>\$'000</b>
Profit after tax	904	402
Tax expense / (benefit)	12	23
Interest expense	347	265
Earnings before interest and tax (EBIT)	1,263	692
Depreciation	138	149
Amortisation	538	424
Earnings before interest, tax, depreciation and amortisation (EBITDA)	1,939	1,265

The Groups financial results are reported under International Financial Reporting Standards (IFRS). This market release also contains non-IFRS measures including EBITDA, EBIT and constant currency. These measures are presented to enable an understanding of the performance of the business before funding, taxation and the treatment of assets is taken into consideration and to review the performance of the business excluding foreign currency movements. The table above explains how EBITDA and EBIT have been calculated.

### **Events subsequent to reporting date**

There are no matters subsequent to half-year end that would materially impact the financial information provided.

### **Auditor's Independence Declaration**

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out on page 8.

## **Rounding of amounts**

The Company is of a kind referred to in Class Order 98/0100 issued by the Australian Securities & Investments Commission, relating to the "rounding off" of amounts in the directors' report and financial report. Amounts in the directors' report and financial report have been rounded off to the nearest thousand dollars in accordance with that Class Order.

This report is made in accordance with a resolution of the directors.

A handwritten signature in black ink, appearing to read 'D. Burton', with a stylized flourish at the end.

D. Burton  
Executive Chairman

Melbourne  
23<sup>rd</sup> February 2015





**Hayes Knight Audit**  
chartered accountants · your partners in success

Hayes Knight Audit Pty Ltd

ABN: 86 005 105 975

Level 12, 31 Queen St,  
Melbourne, VIC 3000

T: 03 8613 8888 F: 03 8613 8800

Email: [info@hayesknighaudit.com.au](mailto:info@hayesknighaudit.com.au)

[www.hayesknight.com.au](http://www.hayesknight.com.au)

Registered Audit Company 291969

**AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE CORPORATIONS ACT 2001 TO THE DIRECTORS OF COMPUMEDICS LIMITED**

I declare that, to the best of my knowledge and belief, during the half-year ended 31 December 2014 there have been:

- a. no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review, and
- b. no contraventions of any applicable code of professional conduct in relation to the review.

**Hayes Knight Audit Pty Ltd**  
Melbourne

**Geoff S. Parker**  
Director

Dated this 23<sup>rd</sup> day of February 2015



**Compumedics Limited**  
**Consolidated statement of profit or loss and other**  
**comprehensive income**  
**for the half-year ended 31 December 2014**

		Half-year 2014 \$'000	Half-year 2013 \$'000
	Notes		
Sale of goods		14,347	13,212
Rendering of services		1,287	1,267
<b>Revenue</b>		<b>15,634</b>	<b>14,479</b>
Cost of sales		(6,712)	(6,588)
<b>Gross profit</b>		<b>8,922</b>	<b>7,891</b>
Other revenue		627	185
Administration		(2,246)	(2,271)
Sales & Marketing		(3,132)	(2,792)
Research & Development		(3,102)	(2,473)
Unrealised foreign exchange gain / (loss)	3	194	150
Finance costs		(347)	(265)
<b>Profit before income tax</b>		<b>916</b>	<b>425</b>
Income tax expense		(12)	(23)
<b>Profit after income tax</b>		<b>904</b>	<b>402</b>
<b>Net profit for the period</b>		<b>904</b>	<b>402</b>
<b>Other comprehensive income</b>			
Items that may be subsequently reclassified to Profit or Loss when specific conditions are met:			
Foreign currency translation		264	75
<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD</b>		<b>1,168</b>	<b>477</b>

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

**Compumedics Limited**  
**Consolidated statement of profit or loss and**  
**comprehensive income**  
**for the half-year ended 31 December 2014**

	Notes	Half-year 2014 \$'000	Half-year 2013 \$'000
<b>Earnings per share for profit attributable to the ordinary equity holders of the parent:</b>		Cents	Cents
Basic earnings per share		0.5	0.2
Diluted earnings per share		0.5	0.2

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

**Compumedics Limited**  
**Consolidated statement of financial position**  
**as at 31 December 2014**

	Notes	31 Dec 2014 \$'000	30 June 2014 \$'000
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents		1,646	1,054
Trade and other receivables		9,210	8,749
Inventories		6,383	6,145
<b>Total current assets</b>		<b>17,239</b>	<b>15,948</b>
<b>Non-current assets</b>			
Property, plant and equipment		604	672
Intangible assets	4	2,679	2,902
<b>Total non-current assets</b>		<b>3,283</b>	<b>3,574</b>
<b>Total assets</b>		<b>20,522</b>	<b>19,522</b>
<b>LIABILITIES</b>			
<b>Current Liabilities</b>			
Trade and other payables		3,999	4,601
Interest bearing liabilities	5	2,557	2,018
Provisions		2,511	2,310
Deferred revenues		970	1,276
Income tax payable		-	39
<b>Total current liabilities</b>		<b>10,037</b>	<b>10,244</b>
<b>Non-current liabilities</b>			
Interest bearing liabilities	5	-	-
Provisions		38	31
Deferred revenues		117	85
<b>Total non-current liabilities</b>		<b>155</b>	<b>116</b>
<b>Total liabilities</b>		<b>10,192</b>	<b>10,360</b>
<b>Net assets</b>		<b>10,330</b>	<b>9,162</b>
<b>EQUITY</b>			
Contributed equity		31,269	31,269
Reserves		(431)	(695)
Retained earnings / (losses)		(20,508)	(21,412)
<b>Total equity</b>		<b>10,330</b>	<b>9,162</b>

The above statement of financial position should be read in conjunction with the accompanying notes.



**Compumedics Limited**  
**Consolidated statement of changes**  
**in equity for the half-year**  
**ended 31 December 2014**

	Contributed equity \$,000	Reserves \$,000	Retained earnings/ (losses) \$,000	Total \$'000
<b>Balance at 1 July 2013</b>	<b>31,269</b>	<b>(595)</b>	<b>(22,321)</b>	<b>8,353</b>
Profit for the period	-	-	402	402
Other comprehensive income / (loss)	-	75	-	75
<b>Total comprehensive income / (loss) for the half year</b>	<b>-</b>	<b>75</b>	<b>402</b>	<b>477</b>
<b>Transactions with owners in their capacity as owners:</b>	-	-	-	-
<b>Balance at 31 December 2013</b>	<b>31,269</b>	<b>(520)</b>	<b>(21,919)</b>	<b>8,830</b>
<b>Balance at 1 July 2014</b>	<b>31,269</b>	<b>(695)</b>	<b>(21,412)</b>	<b>9,162</b>
Profit for the period	-	-	904	904
Other comprehensive income / (loss)	-	264	-	264
<b>Total comprehensive income / (loss) for the half year</b>	<b>-</b>	<b>264</b>	<b>904</b>	<b>1,168</b>
<b>Transactions with owners in their capacity as owners:</b>	-	-	-	-
<b>Balance at 31 December 2014</b>	<b>31,269</b>	<b>(431)</b>	<b>(20,508)</b>	<b>10,330</b>

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

**Compumedics Limited**  
**Consolidated statement of cash flows**  
**for the half-year ended 31 December 2014**

	Notes	Half-year 2014 \$'000	Half-year 2013 \$'000
<b>Cash flows from operating activities</b>			
Receipts from customers (inclusive of goods and services tax)		14,881	16,651
Payments to suppliers and employees (inclusive of goods and services tax)		(14,743)	(15,912)
Receipts from other income		627	184
Income tax paid		(12)	(24)
Interest paid		(345)	(265)
<b>Net cash from operating activities</b>		<b>407</b>	<b>634</b>
<b>Cash flows from investing activities</b>			
Purchase of property, plant and equipment		(315)	(228)
Purchase of intangible assets		(66)	(138)
<b>Net cash (outflow) from investing activities</b>		<b>(381)</b>	<b>(366)</b>
<b>Cash flows from financing activities</b>			
Contributed equity		-	-
Repayments of finance leases		(6)	(63)
Proceeds from borrowings		469	100
Repayment of borrowings		(282)	(400)
<b>Net cash (outflow) from financing activities</b>		<b>181</b>	<b>(363)</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>		<b>207</b>	<b>(95)</b>
Cash and cash equivalents at the beginning of the period		(319)	(105)
Net foreign exchange differences		123	53
<b>Cash and cash equivalents at the end of the period</b>	5	<b>11</b>	<b>(147)</b>

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.

**Compumedics Limited**  
**Notes to the financial statements**  
**for the half-year ended 31 December 2014**

**1 Basis of preparation and accounting policies**

**(a) Basis of preparation**

The general purpose condensed financial report for the half-year ended 31 December 2014 has been prepared in accordance with AASB 134 *Interim Financial Reporting* and the *Corporations Act 2001*.

This half-year financial report does not include all the notes of the type normally included within the annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2014 and any public announcements made by Compumedics Limited during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001* and Australian Stock Exchange Listing Rules.

Apart from the changes in accounting policies noted below, the accounting policies adopted are consistent with the most recent Annual Report for the year ended 30 June 2014.

*Changes in accounting policy*

The accounting policies adopted for the interim condensed consolidated financial statements are consistent with those followed for the preparation of the Group's annual financial statements for the year ended 30 June 2014, and other standards issued as of 1 July 2014 do not have a significant impact on the consolidated financial statements of Compumedics Limited.

The Group has not elected to early adopt any other new standards, amendments or interpretations that are issued but not yet effective.



**Compumedics Limited**  
**Notes to the financial statements**  
**for the half-year ended 31 December 2014**

**(b) Going Concern assumption**

During the half-year ended 31 December 2014, the Group generated a profit after tax of \$0.9m and positive cash flows from operations of \$0.4m. In the corresponding prior half-year the Group generated a profit after tax of \$0.4m and cash flows from operations of \$0.6m.

The Group had a net debt position of \$1.0m at 31 December 2014 (cash at \$1.6m and debt at \$2.6m). The net debt position at June 2014 was \$0.9m (cash at \$1.1m and bank debts at \$2.0m).

The Group was holding orders on-hand at 31 December 2014 of \$3.8m substantially lower than the \$6.0m of orders on-hand at 30<sup>th</sup> June 2014.

The Group is utilising its existing working capital facilities to clear the backlog of orders on-hand and been in a position to meet growing sales orders. The Group obtained additional facilities from EFIC in December in pursuit of this goal.

The Directors believe, based on current information available to them and the on-going support of their primary working-capital provider (BIBBY) and the shareholders who have provided the Company with short-term borrowings, the Company will have sufficient working capital.

As such, the financial report has been prepared on the basis that the Group is a going concern, which assumes the continuity of normal business activities and the realisation of assets and the settlement of liabilities in the ordinary course of business.

**Compumedics Limited**  
**Notes to the consolidated financial statements**  
**for the half-year ended 31 December 2014**

**Note 2. Operating segment**

**Identification of reportable segments**

The Group has identified its operating segments based on the internal reports, which are produced by geographical segment and which are reviewed and used by the chief operating decision maker, being the Chief Executive Officer and Chief Financial Officer, in assessing performance and in determining the allocation of resources.

The operating segments are identified by management based on the country of origin and the senior managers who are responsible for the performance of the business in that geographic territory, the type of product and service provided and whether the product is sold directly to end-user customers or via distributors.

The reportable segments are based on geographic territory as these are the sources of the Group's major risks and have the most effect on rates of return.

**Geographic locations**

Americas

The Group's Americas based business includes, the United States, Canada and Latin America. The Group sells all of its product offerings in this region including sleep diagnostic systems, clinical EEG systems, brain monitoring systems, ultrasonic blood-flow systems, supplies and technical service and support. The USA business also includes the sleep diagnostic services business. Sales in the Americas are predominantly direct sales to end-user customers. The USA office is based in Charlotte, North Carolina.

Australia and Asia Pacific

The Group's head office is based in Melbourne, Australia and the Australia and Asia Pacific territory includes all countries in the Asia Pacific region with major countries for the territory including Japan and China. The Group sells all of its product offerings in this region including sleep diagnostic systems, clinical EEG systems, brain monitoring systems, ultrasonic blood-flow systems, supplies and technical service and support. The group sells directly to end-user customers in Australia and via a network of distributors into the Asian region.

Europe and the Middle East

The Group's Europe-based business has its principal office in Singen, Germany with a second office in Hamburg, Germany. The European territory includes all countries in the European region, plus all Middle Eastern countries. The Group sells all of its product offerings in this region



**Compumedics Limited**  
**Notes to the consolidated financial statements**  
**for the half-year ended 31 December 2014**

**Note 2. Operating segment (continued)**

including sleep diagnostic systems, clinical EEG systems, brain monitoring systems, ultrasonic blood-flow systems, supplies and technical service and support. The Group sells its ultrasonic blood-flow systems directly in Germany and all other products are sold via a network of distributors across the territory.

The following table represents revenue and profit information for reportable segments for the half-years ended 31 December 2014 and 31 December 2013.

**Half-year ended 31 December 2014**

	Continuing operations				
	Australia and Asia				
	USA	Pacific	Europe	Other	Total
	\$'000	\$'000	\$'000	\$'000	\$'000
<b>Revenue</b>					
Sales to external customers	4,332	8,003	3,299	-	15,634
Intersegment sales	286	873	34	-	1,193
Other intersegment revenue	-	44	-	-	44
<b>Total segment revenue</b>	<b>4,618</b>	<b>8,920</b>	<b>3,333</b>	<b>-</b>	<b>16,871</b>
Intersegment elimination	(286)	(917)	(34)	-	(1,237)
<b>Total revenue</b>	<b>4,332</b>	<b>8,003</b>	<b>3,299</b>	<b>-</b>	<b>15,634</b>
<b>Segment Result</b>					
Other income	-	95	532	-	627
Depreciation and amortisation	(7)	(481)	(189)	-	(677)
Finance costs	(94)	(244)	(49)	-	(387)
<b>Net profit or loss before income tax per the statement of profit or loss and other comprehensive income</b>	<b>(1,093)</b>	<b>2,190</b>	<b>(182)</b>	<b>-</b>	<b>915</b>
<b>Segment Assets</b>	<b>2,798</b>	<b>34,033</b>	<b>5,652</b>	<b>-</b>	<b>42,483</b>
Intersegment eliminations	(10)	(22,181)	(64)	-	(22,255)
<b>Total assets per the Statement of Financial Position</b>	<b>2,788</b>	<b>11,852</b>	<b>5,588</b>	<b>-</b>	<b>20,228</b>



**Compumedics Limited**  
**Notes to the consolidated financial statements**  
**for the half-year ended 31 December 2014**

**Half-year ended 31 December 2013**

	<b>Continuing operations</b>				
	<b>Australia and Asia Pacific</b>				
	<b>USA</b>	<b>Pacific</b>	<b>Europe</b>	<b>Other</b>	<b>Total</b>
	<b>\$'000</b>	<b>\$'000</b>	<b>\$'000</b>	<b>\$'000</b>	<b>\$'000</b>
<b>Revenue</b>					
Sales to external customers	4,494	5,967	4,018	-	14,479
Intersegment sales	273	662	77	-	1,012
Other intersegment revenue	-	-	478	-	478
<b>Total segment revenue</b>	<b>4,767</b>	<b>6,629</b>	<b>4,573</b>	<b>-</b>	<b>15,969</b>
Intersegment elimination	(273)	(662)	(555)	-	(1,490)
<b>Total revenue</b>	<b>4,494</b>	<b>5,967</b>	<b>4,018</b>	<b>-</b>	<b>14,479</b>
<b>Segment Result</b>					
Other income	-	106	79	-	185
Depreciation and amortisation	(10)	(477)	(86)	-	(573)
Finance costs					
<b>Net profit or loss before income tax per the statement of profit or loss and other comprehensive income</b>	<b>(956)</b>	<b>1,216</b>	<b>166</b>	<b>-</b>	<b>426</b>
<b>Segment assets</b>	<b>2,520</b>	<b>29,163</b>	<b>5,616</b>	<b>-</b>	<b>37,299</b>
Intersegment eliminations	(35)	(18,460)	(30)	-	(18,525)
<b>Total assets per the Statement of Financial Position</b>	<b>2,485</b>	<b>10,703</b>	<b>5,586</b>	<b>-</b>	<b>18,774</b>

**Compumedics Limited**  
**Notes to the consolidated financial statements**  
**for the half-year ended 31 December 2014**

**Note 3. Other expenses**

On 1 January 2013 the Company reviewed its accounting policy in relation to the translation of intercompany loans to its offshore subsidiaries such that these loans were considered part of the investment in the subsidiary. At the 1<sup>st</sup> July 2014 the German entity was reviewed in relation to this policy and the intergroup loan was considered to be trading in nature. As a consequence currency gains and losses arising on these loans have been taken to the profit and loss whereas the currency gains and losses on the US intergroup loan have been taken to the Foreign Currency Translation Reserve (FCTR). The unrealised foreign exchange gain in the half-year to 31 December 2014 relates to trading activities in the Australian legal entity that are not hedged, net of the currency gain for the German intergroup account.

**Note 4. Intangible assets**

	<b>31 Dec 14</b>	<b>30 Jun 14</b>
	<b>\$'000</b>	<b>\$'000</b>
Intangible asset	2,679	2,902

Intangible assets comprise capitalised development costs associated with the SomniLink® SPAP® sleep-treatment device. Development costs of \$0.3m were capitalised in the half-year to 31 December 2014. Amortisation of \$0.5k is included in the profit and loss for the six months to 31 December 2014. The asset is being amortised over a period of 7 years, through to March 2017.

The Germany-based DWL business capitalises development costs associated with its new Multi-Dop X digital system with Colour Doppler Imaging Module. There were no additional costs capitalised in the current period. Sales have commenced during the 2014 financial year and the intangible assets will be amortised over a 7-year period.

**Compumedics Limited**  
**Notes to the consolidated financial statements**  
**for the half-year ended 31 December 2014**

**Note 5. Cash, Interest bearing liabilities and cash equivalents**

	<b>31 Dec 14 \$'000</b>	<b>30 Jun 14 \$'000</b>
Current interest bearing liabilities	2,557	1,918
Non-current interest bearing liabilities	-	100
<b>Total interest bearing liabilities</b>	<b>2,557</b>	<b>2,018</b>
<b>Current interest bearing liabilities comprise:</b>		
Invoice financing facility	1,635	1,431
Fixed term borrowings	903	460
Other – lease commitments	19	27
Total current interest bearing liabilities	2,557	1,918
<b>Cash and cash equivalents</b>		
Cash	1,646	1,285
Overdraft and trade facility	(1,635)	(1,432)
Cash and cash equivalents	11	(147)

Interest bearing liabilities comprise an invoice financing facility provided by the Groups third party financier and fixed term commercial loans provided by the Groups shareholders together with hire purchase facilities.

There were four fixed term commercial loans. The first loan, with an outstanding balance of \$0.25m at 30 June 2014 had repayments made against it of \$0.17m in the six month period, leaving a balance at 31 December 2014 of \$0.08m, with the balance having been repaid as at the date of this report. The second loan for \$0.1m is due for repayment June 2015. The third loan for \$0.1m is due for repayment September 2015 and the fourth loan for \$0.1m is due for repayment February 2016. All loans may be extended for, up to a further 12-month period, subject to mutual consent.

The Group reports cash flows back to cash and cash equivalents as noted in the table above, by subtracting the invoice financing facility from actual cash held by the Group at reporting date.



**Compumedics Limited**  
**Notes to the consolidated financial statements**  
**for the half-year ended 31 December 2014**

**Note 6. Commitments**

The Group has lease commitments relating to the offices it runs the business from in Melbourne, Charlotte, Singen, Hamburg and El Paso. The total commitments under these leases are:

Approximate lease commitments due within one year are \$743k

Approximate lease commitments due greater than one year are \$839k

**Note 7. Events occurring after reporting date**

There are no matters subsequent to half-year end that would materially impact the financial information provided.

**Compumedics Limited**  
**Directors' Declaration**  
**for the half-year ended 31 December 2014**

In accordance with a resolution of the Directors of Compumedics Limited I state that:

In the opinion of the directors':

(a) the financial statements and notes set out on pages 9 to 21 are in accordance with the *Corporations Act 2001*, including:

(i) complying with Accounting Standard AASB 134 *Interim Financial Reporting*, the *Corporations Regulations 2001* and other mandatory professional reporting requirements; and

(ii) giving a true and fair view of the consolidated entity's financial position as at 31 December 2014 and of its performance, as represented by the results of its operations, changes in equity and its cash flows, for the half-year ended on that date; and

(b) there are reasonable grounds to believe that Compumedics Limited will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the directors.



David Burton  
Executive Chairman

Melbourne  
23<sup>rd</sup> February 2015



## INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF COMPUMEDICS LIMITED

### Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Compumedics Limited and Controlled Entities ("the consolidated entity") which comprises the condensed consolidated statement of financial position as at 31 December 2014, the condensed consolidated statement of profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

### Directors' Responsibility for the Half-Year Financial Report

The directors of the consolidated entity are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

### Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entity's financial position as at 31 December 2014 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134: *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of Compumedics Limited and Controlled Entities, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*. We confirm that the independence declaration required by the *Corporations Act 2001* has been provided to the directors of Compumedics Limited.



## Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Compumedics Limited and Controlled Entities is not in accordance with the *Corporations Act 2001* including:

- a. giving a true and fair view of the consolidated entity's financial position as at 31 December 2014 and of its performance for the half-year ended on that date; and
- b. complying with Accounting Standard AASB 134 *Interim Financial Reporting* and *Corporations Regulations 2001*.

*Hayes Knight Audit*

Hayes Knight Audit Pty Ltd  
Melbourne



Geoff S. Parker  
Director

Dated this 23<sup>rd</sup> day of February 2015

## Compumedics Limited Supplementary Appendix 4D information for the half-year ended 31 December 2014

### **Additional dividend/distribution information<sup>2</sup>** *(Appendix 4D item 5)*

Details of dividends/distributions declared or paid during or subsequent to the year ended 31 December 2014 are as follows:

Record date	Payment date	Type	Amount per security	Total dividend	Franked amount per security	Foreign sourced dividend amount per security
N/A	N/A	N/A	N/A	N/A	N/A	N/A

### **Dividend/distribution reinvestment plans** *(Appendix 4D item 6)* **NOT APPLICABLE**

### **Material factors affecting the revenues and expenses of the economic entity for the current period**

The major impacts to the revenues and expenses of the economic entity in the half-year to 31 December 2014 have already been disclosed elsewhere in this document.

### **Material factors affecting the assets, liabilities and equity of the economic entity for the current period**

The major factors impacting the assets and liabilities of the Company relate to the on-going focus of the Company on enhancing its financial performance. In this half year period as noted the movement in the Australian dollar to the US dollar and the Euro has also impacted the assets and liabilities of the Company.

### **Material factors affecting the cash flows of the economic entity for the current period**

The major factors impacting the cash flows of the Company relate to the on-going focus of the Company on enhancing its financial performance. In this half year period as noted the movement in the Australian dollar to the US dollar and the Euro has also impacted the assets and liabilities of the Company.